乳腺癌原发灶和复发及转移灶中ER、PR、HER—2、Ki67的变化及其临床意义

2018-08-29 02:15:34朱磊潘颖周毅程枫程雪
中国现代医生 2018年13期
关键词:乳腺癌差异检测

朱磊 潘颖 周毅 程枫 程雪

[摘要] 目的 探討乳腺癌复发及转移灶与原发灶中ER、PR、HER-2、Ki67的表达差异及其临床意义。 方法 选取我院70例复发性乳腺癌患者,分别分析原发病灶及对应的复发转移灶肿瘤组织中的ER、PR、HER-2及Ki67免疫组化表达情况。 结果 乳腺癌局部复发和远处转移组与肿瘤分级(P=0.000)、肿瘤TNM分期(P=0.002)有统计学意义(P<0.05);与患者的年龄(P=0.873)、是否绝经(P=0.540)、腋窝淋巴结的转移(P=0.556),差异无统计学意义。原发灶和复发转移灶前后表达变化的差异经χ2检验(ER:χ2=0.507,P=0.476;PR:χ2=0.714,P=0.398;HER-2:χ2=2.287,P=0.130;Ki67:χ2=10.683,P=0.001),提示在原发灶和复发转移灶之间ER、PR、HER-2的表达总体分布基本相同,差异无统计学意义(P>0.05),Ki67的表达变化总体分布不同,差异有统计学意义(P<0.05);原发灶和复发转移灶ER、PR及Ki67表达一致性差异有统计学意义(P<0.05)。 结论 在乳腺癌原发和复发转移灶的分子标志物中ER、PR和Ki67的表达存在不一致性,HER-2的表达有较高的一致性。检查乳腺癌复发转移灶中各项分子指标的表达对选择个体化的治疗方案及评估预后有重要意义。

[关键词] 乳腺癌;原发灶;复发;转移;ER;PR;HER-2;Ki67

[中图分类号] R737.9 [文献标识码] A [文章编号] 1673-9701(2018)13-0014-04

The change and clinical significance of ER, PR, HER-2 and Ki67 in primary tumor, recurrence and metastasis of breast cancer

ZHU Lei PAN Ying ZHOU Yi CHENG Feng CHENG Xue

Department of Thyroid and Breast Surgery, the Central Hospital of Lishui City in Zhejiang Province, Lishui 323000, China

[Abstract] Objective To investigate the difference of expression and its clinical significance of ER, PR,HER-2 and Ki67 in the primary tumor, recurrence and metastasis of breast cancer. Methods 70 patients with recurrence of breast cancer in our hospital were selected. The immunohistochemical expression of ER, PR, HER-2 and Ki67 in the primary tumor and corresponding recurrence and metastasis were analyzed respectively. Results The incidence of local recurrence and distant metastasis of breast cancer was significantly associated with tumor grade(P=0.000) and tumor TNM stage(P=0.002)(P<0.05). The incidence of them was not significantly associated with age of patient(P=0.873), menopause (P=0.540) and axillary lymph node metastasis(P=0.556). The χ2 test was used to examine the difference of expression before and after the primary tumor, recurrence and metastasis (ER:χ2=0.507,P=0.476;PR:χ2=0.714,P=0.398;HER-2:χ2=2.287,P=0.130; Ki67:χ2=10.683,P=0.001), suggesting the overall distribution of the expression of ER, PR and HER-2 was not statistically different(P>0.05) and the overall distribution of Ki67 expression was statistically different (P<0.05). The expression of ER, PR and Ki67 in recurrence and metastasis was significantly consistent(P<0.05). Conclusion The expression of ER, PR and Ki67 in primary tumor, recurrence and metastasis was inconsistent while the expression of HER-2 was highly consistent.Assessment of the expression of these biomarkers in recurrence and metastasis of breast cancer was important for individualized treatment regimen selection and the evaluation of prognosis.

[Key words] Breast cancer; Primarytumor; Recurrence; Metastasis; ER; PR; HER-2; Ki67

女性最常见的恶性肿瘤之一的乳腺癌其发病率呈逐年上升的趋势,目前已居于女性恶性肿瘤发病率的第一位[1]。近年来乳腺癌随着诊断技术的进步和治疗方法的新应用,使得总体生存率明显提高,但乳腺癌复发和远处转移仍较多见,15%~20%的乳腺癌患者术后5年内会出现原位或远处转移[2]。目前临床检测乳腺癌组织中免疫组化分子生物学标志主要有:ER、PR、HER-2、Ki67,其表达已成为指导乳腺癌治疗、预后判断的主要依据。复发性乳腺癌的治疗策略通常也是根据原发性病灶的病理诊断信息来确定。然而以ER、PR、HER-2、Ki67为代表的乳腺癌分子生物学标志偶尔在复发时会发生变化[3-6]。因此复发性肿瘤的病理评估也成为指导治疗策略的重要信息。本研究通过分析乳腺癌原发灶和复发及转移灶之间的分子生物学标志的差异表达,并总结其特征和变化规律,从而达到为复发和转移患者的后续个体化治疗策略及预后评估提供参考的目的。

1 资料与方法

1.1 一般资料

登录APP查看全文

猜你喜欢
乳腺癌差异检测
绝经了,是否就离乳腺癌越来越远呢?
中老年保健(2022年6期)2022-08-19 01:41:48
相似与差异
音乐探索(2022年2期)2022-05-30 21:01:37
找句子差异
乳腺癌是吃出来的吗
胸大更容易得乳腺癌吗
生物为什么会有差异?
别逗了,乳腺癌可不分男女老少!
祝您健康(2018年5期)2018-05-16 17:10:16
小波变换在PCB缺陷检测中的应用
M1型、M2型巨噬细胞及肿瘤相关巨噬细胞中miR-146a表达的差异